title: Bone mineral density in systemic lupus erythematosus women one year after rituximab therapy.
abstract: The objective of this study was to assess the effects of rituximab on bone mineral density (BMD) in women with systemic lupus erythematosus (SLE) 1 year after treatment. Thirty active female SLE patients treated with rituximab were compared with 43 SLE women not treated with rituximab. BMD was measured using dual energy X-ray absorptiometry (DEXA) before initiating biologic therapy and after 1 year. The mean age was 38.5 ± 2.1 years; median disease duration was 7 years. In the rituximab group, after 1 year of follow-up, BMD at the femoral neck (FN) decreased from 0.980 ± 0.130 g/cm(2) to 0.809 ± 0.139 g/cm(2) (-17.4%; p=0.001). Similarly, BMD at the lumbar spine (LS) decreased from 1.062 ± 0.137 g/cm(2) to 0.893 ± 0.194 g/cm(2) (-15.8%; p=0.001). In control subjects, BMD at the FN decreased from 0.914 ± 0.193 g/cm(2) to 0.890 ± 0.135 g/cm(2) (-2.6%; p=0.001), and BMD at the LS decreased from 0.926 ± 0.128 g/cm(2) to 0.867 ± 0.139 g/cm(2) (-6.2%; p=0.09). After 1 year, SLE patients had lower BMD at both the FN and LS, but the loss was greater in postmenopausal patients who had received rituximab therapy.
authors.affiliation: 1Systemic Autoimmune Diseases Research Unit, IMSS, Puebla, México; Department of Immunology and Rheumatology, BUAP, Puebla, México; Department of Epidemiology and Health Public, BUAP, Puebla, México; Department of Radiology, Laboratorios Clínicos de Puebla, México; Direction of Education and Research, IMSS, Puebla, México; State Research Department, Research Unit, IMSS, Puebla, México; and Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Mendoza Pinto
authors.forename: M
authors.initials: M
authors.lastname: García Carrasco
authors.forename: I
authors.initials: I
authors.lastname: Etchegaray Morales
authors.forename: M
authors.initials: M
authors.lastname: Jiménez Hernández
authors.forename: S
authors.initials: S
authors.lastname: Méndez Martínez
authors.forename: C
authors.initials: C
authors.lastname: Jiménez Hernández
authors.forename: R
authors.initials: R
authors.lastname: Briones Rojas
authors.forename: G
authors.initials: G
authors.lastname: Ramos Alvarez
authors.forename: A
authors.initials: A
authors.lastname: Rodríguez Gallegos
authors.forename: A
authors.initials: A
authors.lastname: Montiel Jarquín
authors.forename: A
authors.initials: A
authors.lastname: López Colombo
authors.forename: R
authors.initials: R
authors.lastname: Cervera
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000502:physiology; D015519:Bone Density / Q000187:drug effects*; D005260:Female; D005938:Glucocorticoids / Q000494:pharmacology; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000378:metabolism; D011446:Prospective Studies; D000069283:Rituximab; D013997:Time Factors
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D005938:Glucocorticoids; D000069283:Rituximab
keywords: bone mineral density; rituximab; systemic lupus erythematosus